Aligos Therapeutics, Inc. (ALGS) Financials
ALGS Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 64.6 million | 32.8 million |
| Dec. 31, 2025 | 89.6 million | 36.0 million |
| Sept. 30, 2025 | 109.8 million | 37.9 million |
| June 30, 2025 | 134.7 million | 32.8 million |
ALGS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -23.2 million | 1.3 million |
| Dec. 31, 2025 | -21.8 million | 1.5 million |
| Sept. 30, 2025 | -24.5 million | 1.5 million |
| June 30, 2025 | -15.6 million | 1.2 million |
ALGS Net Income
No data available :(
ALGS Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 55.1 million | - | 659000 |
| Dec. 31, 2025 | 78.0 million | - | 1.5 million |
| Sept. 30, 2025 | 99.1 million | - | 6.1 million |
| June 30, 2025 | 122.9 million | - | 6.9 million |
ALGS Shares Outstanding
ALGS Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 69000 | 23.4 million | 6.4 million | - |
| Dec. 31, 2025 | 92000 | 17.0 million | 4.7 million | - |
| Sept. 30, 2025 | 193000 | 23.9 million | 5.2 million | - |
| June 30, 2025 | 109000 | 14.0 million | 5.6 million | - |
ALGS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 2.8 million | - |
| Dec. 31, 2025 | 169000 | 257000 |
| Sept. 30, 2025 | 741000 | - |
| June 30, 2025 | 965000 | 259000 |
ALGS
Price: $5.28
52 week price:
Earnings Per Share: -9.78 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 78576
Market Capitalization: 31.8 million